The public needs more protection from Big Pharma profiteering off of billions in taxpayer funded drug research.
Young adults living with diabetes are rationing insulin and dying when they age out of their parents’ insurance plans.
We want patients to buy prescriptions at reasonable prices, but we can’t rely on our northern neighbor forever.
Campaign Relaunches in Light of Recent Setbacks For Administration Blueprint
Americans wanted to list drug price ads on TV. Big Pharma and a federal judge said no.
"More than 3,400 drugs have boosted their prices in the first six months of 2019, an increase of 17% in the number of drug hikes from a year earlier."
Sneaky pharma tactics are keeping lifesaving generic drugs out of reach for patients who need them most.
So many bipartisan drug pricing proposals, so little time.
The US pays two to three times more than other developed nations for prescription drugs.
The DOJ wants a jury trial for Mallinckrodt, the company at the heart of a 97,000 percent price spike for a gel mainly used to treat infant seizures.
The Senate would give the state’s Health Policy Commission authority to demand information from drug companies that have failed to reach a negotiated price with the state secretary of health and human services.
After drug prices for MassHealth doubled in five years, Governor Charlie Baker and the state legislature are advancing budget proposals that would require drug companies to justify exorbitant prices and allow the state to negotiate drug costs on behalf of patients and taxpayers.
Colorado is the first state to place a price cap on out-of-control insulin prices.
Spunky Maryland’s new drug pricing affordability board will be enacted July 1. We expect more reforms to come from states this year.
We need legislation to stop deals for delay and patent thickets, AbbVie’s monopolistic bread and butter.
Senators John Cornyn, a Texas Republican, and Richard Blumenthal, a Connecticut Democrat, proposed legislation this week to stop drug companies’ abusive patent tactics that block competition and crush taxpayers and patients.
In the first three months of 2019, PhRMA spent $10 million for 27 in-house lobbyists and 20 outside lobbyists. Swampy.
Welcome to the week in drug pricing news — no redactions.
New data from the Centers For Medicare & Medicaid Services emphasized the need for Congress to pass the CREATES Act, a bipartisan bill that would lower drug prices and save taxpayers billions.